<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1611">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073500</url>
  </required_header>
  <id_info>
    <org_study_id>PSM_250913</org_study_id>
    <nct_id>NCT02073500</nct_id>
  </id_info>
  <brief_title>Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies</brief_title>
  <acronym>PSM</acronym>
  <official_title>Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify biomarkers of disease recurrence and prognosis to
      optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic
      intraperitoneal chemotherapy (HIPEC), and through animal models to explore different
      treatment strategies for peritoneal surface malignancies (PSM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The handling of patients with PSM involves multimodal and multidisciplinary treatment
      strategies such as CRS, the removal of all macroscopically detectable tumor, and HIPEC,
      instillation of heated chemotherapy in the abdominal cavity to remove residual cancer
      disease. The treatment is challenging and complex and associated with significant morbidity.
      Only patients with limited disease will benefit from the treatment, and better methods for
      patient selection are needed. The project group has a unique opportunity to address key
      questions because of acquired experience, an exceptional biobank and institutional database
      and novel animal models established at the Norwegian Radium Hospital.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pseudomyxoma Peritonei.</condition>
  <condition>Colorectal Carcinoma.</condition>
  <condition>Ovarian Carcinoma.</condition>
  <condition>Mesothelioma.</condition>
  <arm_group>
    <arm_group_label>Observational study</arm_group_label>
    <description>Patients diagnosed with PSM undergoing CRS with HIPEC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study.</intervention_name>
    <description>Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.
HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.</description>
    <arm_group_label>Observational study</arm_group_label>
    <other_name>Observational study. Laboratory biomarker analysis.</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Metastatic tissue, blood specimens.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with PSM that are referred to Oslo University Hospital and are candidates for
        CRS with HIPEC may be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  confirmed diagnosis of  peritoneal surface malignancy

          -  candidate for CRS-HIPEC

          -  written informed consent

        Exclusion Criteria:

          -  none

        Approximately 80 patients per year will be eligible for inclusion, as this is the number
        of patients that annually receive surgical treatment for PSM.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjersti Flatmark, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kjersti Flatmark, MD PhD</last_name>
    <phone>+47 22 78 18 73</phone>
    <email>Kjersti.Flatmark@rr-research.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Torgunrud Kristensen, PhD</last_name>
    <phone>+47 22 78 23 12</phone>
    <email>atj@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjersti Flatmark, MD PhD</last_name>
      <phone>+47 22 78 18 73</phone>
      <email>Kjersti.Flatmark@rr-research.no</email>
    </contact>
    <contact_backup>
      <last_name>Annette Torgunrud Kristensen, PhD</last_name>
      <phone>+47 22 78 23 12</phone>
      <email>atj@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Kjersti Flatmark, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal carcinomatosis</keyword>
  <keyword>Peritoneal surface malignancy</keyword>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>CRS</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Prognostic biomarker</keyword>
  <keyword>Predictive biomarker</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Pseudomyxoma Peritonei</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
